Press

Featured In

BusinessWire
October 8, 2024

First Patient Dosed with NILK-2401 in Phase I Clinical Trial

Featured In

Applied Clinical Trials
September 18, 2024

DPharm 2024: Problem Solving in the Clinical Trial Realm

Featured In

Opna Bio
August 26, 2024

Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor

Featured In

BusinessWire
August 19, 2024

MOMA Therapeutics Announces Initiation of Phase 1 Clinical Trial for MOMA-313, a Novel Polymerase Theta Helicase Inhibitor

Featured In

Clinical Leader
July 29, 2024

Why Moving More Cancer Trials Into the Community Benefits Patients and Sponsors

Featured In

Biotheryx
July 17, 2024

Biotheryx Announces First Patient Dosed in Phase 1 Clinical Trial of BTX-9341, a First-in-Class, Dual Bifunctional Degrader of CDK4/6, as a Monotherapy and in Combination with Fulvestrant for HR+/HER2- Breast Cancer
Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.

Varius nec, elit turpis amet, proin ut sed nec donec auctor dolor arcu, sollicitudin.

Contact Us
Enim nulla elementum sodales dapibus orci, sed quam mattis aliquam dui penatibus aliquet feugiat nisl laoreet placerat pellentesque duis semper pellentesque tempor placerat nam parturient magna volutpat auctor mattis imperdiet sapien ut tortor id amet tempor tortor, augue facilisi mi.